Refractory multisystemic sarcoidosis, a diagnosis and treatment challenge: a case report

Abstract

Background Sarcoidosis is a multisystemic granulomatous disease of unknown origin. It is characterized by abnormal activation of lymphocytes and macrophages with the formation of granulomas. Most cases have asymptomatic pulmonary involvement. In case of symptoms, they have an excellent response to glucocorticoid therapy. We present a case of sarcoidosis with multi-organ involvement, refractory to multiple treatments including biological. Partial remission was achieved in it. Case presentation We report an interesting case of a 38-years-old Spanish woman treated by Heerfordt’s syndrome (uveitis, parotiditis, fever and facial palsy) plus pulmonary hiliar adenopathy. A sarcoidosis diagnosis was confirmed by lung biopsy. She was initially treated with an 8 weeks course of medium dose oral glucocorticoids and tapered over 8 weeks with improvement. After the suspension of glucocorticoids a relapse occurs with severe ocular involvement and suspicion of neurological involvement. The patient received multiple lines of treatment with poor response. Finally, after the combination of cyclophosphamide with infliximab, the uveitis resolved, improving the neurological symptoms. Conclusions Sarcoidosis is a benign disease in most cases. In a small percentage of cases behaves aggressively, requiring early diagnosis and immunosuppressive treatment to avoid sequelae. An adequate immunosuppressive therapy based on Anti TNF drugs should be started to minimize damage and improve the quality of life.The choice of treatment depends on the type and severity of the disease.

Hyperuricemia research progress in model construction and traditional Chinese medicine interventions

“…Although these drugs can somewhat treat HUA, they have unavoidable side effects and clinical limitations ( Saag et al, 2022 ). Therefore, developing safer and more effective therapeutic strategies for HUA is necessary ( Flores et al, 2023 ).…”

“…Frontiers in Pharmacology frontiersin.org 2022). Therefore, developing safer and more effective therapeutic strategies for HUA is necessary (Flores et al, 2023).…”